128 related articles for article (PubMed ID: 38272376)
1. Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.
Papi A; Castro M; Corren J; Pavord ID; Tohda Y; Altincatal A; Pandit-Abid N; Laws E; Akinlade B; Mannent LP; Gall R; Jacob-Nara JA; Deniz Y; Rowe PJ; Lederer DJ; Hardin M
Respir Med; 2024 Apr; 224():107535. PubMed ID: 38272376
[TBL] [Abstract][Full Text] [Related]
2. Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose.
Pavord ID; Bourdin A; Papi A; Domingo C; Corren J; Altincatal A; Radwan A; Pandit-Abid N; Jacob-Nara JA; Deniz Y; Rowe PJ; Laws E; Lederer DJ; Hardin M
Allergy; 2023 Nov; 78(11):2921-2932. PubMed ID: 37431558
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.
Wechsler ME; Ford LB; Maspero JF; Pavord ID; Papi A; Bourdin A; Watz H; Castro M; Nenasheva NM; Tohda Y; Langton D; Cardona G; Domingo C; Park HS; Chapman KR; Mao X; Zhang Y; Khan AH; Deniz Y; Rowe PJ; Kapoor U; Khokhar FA; Mannent LP; Ruddy M; Laws E; Amin N; Hardin M
Lancet Respir Med; 2022 Jan; 10(1):11-25. PubMed ID: 34597534
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab improves long-term outcomes in patients with uncontrolled, moderate-to-severe GINA-based type 2 asthma, irrespective of allergic status.
Rabe KF; Pavord ID; Busse WW; Chupp GL; Izuhara K; Altincatal A; Gall R; Pandit-Abid N; Deniz Y; Rowe PJ; Jacob-Nara JA; Radwan A
Allergy; 2023 Aug; 78(8):2148-2156. PubMed ID: 37073882
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab long-term efficacy in patients with non-OCS-dependent asthma with and without evidence of allergic asthma.
Sher LD; Corren J; Pavord ID; Daizadeh N; Altincatal A; Soler X; Djandji M; Radwan A; Jacob-Nara JA; Deniz Y; Rowe PJ
J Asthma; 2023 Sep; 60(9):1767-1774. PubMed ID: 36876957
[TBL] [Abstract][Full Text] [Related]
6. Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.
Corren J; Katelaris CH; Castro M; Maspero JF; Humbert M; Halpin DMG; Altincatal A; Pandit-Abid N; Soler X; Radwan A; Jacob-Nara JA; Deniz Y; Rowe PJ
ERJ Open Res; 2023 Sep; 9(5):. PubMed ID: 37859672
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline.
Bourdin A; Virchow JC; Papi A; Lugogo NL; Bardin P; Antila M; Halpin DMG; Daizadeh N; Djandji M; Ortiz B; Jacob-Nara JA; Gall R; Deniz Y; Rowe PJ
Respir Med; 2022 Oct; 202():106938. PubMed ID: 36087550
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE study.
Tohda Y; Nakamura Y; Fujisawa T; Ebisawa M; Msihid J; Djandji M; Ortiz B; Jacob-Nara JA; Deniz Y; Rowe PJ; Ishida M; Arima K
Allergol Int; 2023 Jan; 72(1):89-99. PubMed ID: 36114102
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma.
Papi A; Corren J; Castro M; Domingo C; Rogers L; Chapman KR; Jackson DJ; Daizadeh N; Pandit-Abid N; Gall R; Jacob-Nara JA; Rowe PJ; Deniz Y; Ortiz B
Allergy; 2023 Jan; 78(1):233-243. PubMed ID: 35899469
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization.
Corren J; Hanania NA; Busse WW; Sher LD; Altincatal A; Hardin M; Mannent LP; Amin N; Lederer DJ; Soler X; Jacob-Nara JA; Rowe PJ; Deniz Y
Clin Exp Allergy; 2023 Oct; 53(10):1020-1030. PubMed ID: 37752621
[TBL] [Abstract][Full Text] [Related]
11. Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study.
Menzies-Gow A; Ambrose CS; Colice G; Hunter G; Cook B; Molfino NA; Llanos JP; Israel E
Adv Ther; 2023 Nov; 40(11):4957-4971. PubMed ID: 37723356
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma.
Castro M; Rabe KF; Corren J; Pavord ID; Katelaris CH; Tohda Y; Zhang B; Rice MS; Maroni J; Rowe P; Pirozzi G; Amin N; Ruddy M; Akinlade B; Graham NMH; Teper A
ERJ Open Res; 2020 Jan; 6(1):. PubMed ID: 32010719
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study.
Tohda Y; Nakamura Y; Fujisawa T; Ebisawa M; Arima K; Miyata M; Takahashi Y; Rice MS; Deniz Y; Rowe P; Patel N; Graham NMH; Teper A
Allergol Int; 2020 Oct; 69(4):578-587. PubMed ID: 32444306
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial.
Sher LD; Wechsler ME; Rabe KF; Maspero JF; Daizadeh N; Mao X; Ortiz B; Mannent LP; Laws E; Ruddy M; Pandit-Abid N; Jacob-Nara JA; Gall R; Rowe PJ; Deniz Y; Lederer DJ; Hardin M
Chest; 2022 Jul; 162(1):46-55. PubMed ID: 35217003
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study.
Bacharier LB; Guilbert TW; Katelaris CH; Deschildre A; Phipatanakul W; Liu D; Altincatal A; Mannent LP; Amin N; Laws E; Akinlade B; Jacob-Nara JA; Deniz Y; Rowe PJ; Lederer DJ; Hardin M
J Allergy Clin Immunol Pract; 2024 Apr; 12(4):948-959. PubMed ID: 38092225
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction.
Hanania NA; Castro M; Bateman E; Pavord ID; Papi A; FitzGerald JM; Maspero JF; Katelaris CH; Singh D; Daizadeh N; Altincatal A; Pandit-Abid N; Soler X; Siddiqui S; Laws E; Jacob-Nara JA; Rowe PJ; Lederer DJ; Hardin M; Deniz Y
Ann Allergy Asthma Immunol; 2023 Feb; 130(2):206-214.e2. PubMed ID: 36332763
[TBL] [Abstract][Full Text] [Related]
17. Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma.
Corren J; Katelaris CH; Castro M; Maspero JF; Ford LB; Halpin DMG; Rice MS; Radwan A; Deniz Y; Rowe PJ; Teper A; Djandji M
Eur Respir J; 2021 Oct; 58(4):. PubMed ID: 34266940
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose.
Domingo C; Rabe KF; Price D; Brusselle G; Wechsler ME; Xia C; Pandit-Abid N; Gall R; Rowe PJ; Deniz Y; Jacob-Nara JA; Radwan A
ERJ Open Res; 2023 Nov; 9(6):. PubMed ID: 38020559
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST study.
Maspero JF; Cardona G; Schonffeldt P; Tolcachier A; González-Diaz SN; Yañez A; Galvao CE; Msihid J; Gall R; Siddiqui S; Rowe PJ; Deniz Y; Jacob-Nara JA; Djandji M
J Asthma; 2023 May; 60(5):981-990. PubMed ID: 36066123
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps.
Berger P; Menzies-Gow A; Peters AT; Kuna P; Rabe KF; Altincatal A; Soler X; Pandit-Abid N; Siddiqui S; Jacob-Nara JA; Deniz Y; Rowe PJ
Ann Allergy Asthma Immunol; 2023 Feb; 130(2):215-224. PubMed ID: 36356712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
